Novartis and Amgen have entered into a neuroscience collaboration, based around a programme looking for a potential oral Alzheimer’s treatment.
The companies will partner in the development and commercialisation of a BACE inhibitor programme in Alzheimer’s, with Novartis’ oral therapy CNP520 as the lead molecule. The collaboration will also focus on new Amgen drugs in the migraine field, including the Phase III compound AMG 334 and AMG 301, which is in Phase I.
Under the terms of the Alzheimer’s deal, Amgen will pay an undisclosed upfront fee and milestone payments as well as disproportional R&D costs for a period, followed by a 50/50 cost and profit share arrangement. Novartis says CNP520, which is in Phase I/IIa, is designed to prevent the production of different forms of amyloid and has the potential to prevent, slow or delay the symptoms associated with Alzheimer’s.
CNP520 is also planned to be included in a pioneering prevention study in people with a genetic risk of developing the disease, in collaboration with the Banner Alzheimer’s Institute.